Tomohiro Nishina

Shikoku Cancer Center — Japan

Medicine · Health Sciences

48h-index10.0kcitations483works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(228), Gastric Cancer Management and Outcomes(175), Cancer Genomics and Diagnostics(86), Genetic factors in colorectal cancer(62), Gastrointestinal Tumor Research and Treatment(58)

Publications480 total

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Future Oncology·2025· 2 citedOpen Access
738P Impact of prior anti-EGFR therapy (EGFRi) on efficacy of pertuzumab (PER) plus trastuzumab (TRA) for HER2-positive (HER2+) metastatic colorectal cancer (mCRC): TRIUMPH/MyPathway integrated analysis
Annals of Oncology·2025
EHR-PHR Linkage Platform for Managing Personalized Healthcare Processes Within Clinical Pathways
Studies in health technology and informatics·2025Open Access
<scp>ONO</scp>‐4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Cancer Science·2025· 1 citedOpen Access
Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of <scp>EGFR</scp> Inhibitors in <scp>RAS</scp> Wild‐Type Metastatic Colorectal Cancer: Ancillary Analysis of <scp>FAEISS</scp> Study (<scp>NCCH1512</scp>)
The Journal of Dermatology·2025Open Access
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
ESMO Gastrointestinal Oncology·2025· 1 citedOpen Access
Landscape Analysis of <scp><i>CLDN18</i></scp> Expression and Isoform Distribution in Solid Tumors: Insights From <scp>MONSTAR</scp>‐<scp>SCREEN</scp>‐2 Study
Cancer Science·2025· 3 citedOpen Access
Supplementary Figure S4 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Table 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S6 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S9 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Table 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S5 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S11 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Table S3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Table S1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Figure 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Data from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S10 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
page 1 of 24Next →

Frequent Co-authors

Kensei Yamaguchi(24), Takayuki Yoshino(19), Kei Muro(18), Yoshito Komatsu(18), Taito Esaki(17), Atsushi Ohtsu(15), Narikazu Boku(14), Akihito Tsuji(13), Kohei Shitara(12), Shuichi Hironaka(12), Ichinosuke Hyodo(11), Hideaki Bando(11), Kentaro Yamazaki(11), Naotoshi Sugimoto(9), Takeharu Yamanaka(9), Eiji Shinozaki(9), Hiroki Hara(8), Masahiro Tsuda(8), Toshikazu Moriwaki(8), Tadamichi Denda(8)